A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma

被引：0

作者：

Salles, Gilles ^{[1
]}

Shah, Harsh ^{[2
]}

Leonard, John P. ^{[3
]}

Szanto, Attila ^{[4
]}

Chen, Jade ^{[4
]}

Bannerji, Rajat ^{[4
]}

Morschhauser, Franck ^{[5
]}

Nastoupil, Loretta J. ^{[6
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Univ Utah, Salt Lake City, UT USA

[3] Weill Cornell Med, New York, NY USA

[4] Epizyme, Cambridge, MA USA

[5] Univ Lille, CHU Lille, ULR 7365, GRITA,Grp Rech Formes Injectables & Technol Assoc, Lille, France

[6] UT MD Anderson Canc Ctr, Houston, TX USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

IBCL; follicular lymphoma; non-Hodgkin lymphoma; enhancer of zeste homolog 2 protein; epigenetics; tazemetostat; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-485

引用

页码：S454 / S455

页数：2

共 50 条

[21] A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.
Sen, Shiraj
McKean, Meredith Ann
Sierra, Laura
Ainscough, Jessica
Yang, Jay
Hamlett, Anthony
Zimmerman, Tom
Merchant, Melinda
Chawla, Sant P.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[22] Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update
Lorenzo, Falchi
Sirpa, Leppa
Wahlin, Bjorn E.
Marcel, Nijland
Christensen, Jacob H.
De, Vos Sven
Harald, Holte
Linton, Kim M.
Aqeel, Abbas
Wang Liwei
Minh, Dinh
Brian, Elliott
David, Belada
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S31
[23] Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine plus Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data
Zinzani, Pier Luigi
Topp, Max S.
Yuen, Sam L. S.
Rusconi, Chiara
Fleury, Isabelle
Pro, Barbara
Gritti, Giuseppe
Crump, Michael
Hsu, Wanling
Punnoose, Elizabeth A.
Hilger, James
Mobasher, Mehrdad
Hiddermann, Wolfgang
BLOOD, 2016, 128 (22)
[24] Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide plus rituximab (R2) vs. rituximab plus placebo in relapsed/refractory indolent non-Hodgkin lymphoma
Izutsu, Koji
Minami, Yosuke
Fukuhara, Noriko
Terui, Yasuhito
Jo, Tatsuro
Yamamoto, Go
Ishikawa, Takayuki
Kobayashi, Tsutomu
Kiguchi, Toru
Nagai, Hirokazu
Ohtsu, Tomoko
Kalambakas, Stacey
Fustier, Pierre
Midorikawa, Shuichi
Tobinai, Kensei
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (03) : 409 - 416
[25] AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL)
Leonard, John
Gribben, John G.
Trneny, Marek
Scheinberg, Phillip
Kilavu, Nurgul
Patturajan, Moore
Fustier, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[26] Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
Kersten, Marie Jose
Dreyling, Martin
Linton, Kim M.
Chitu, Dana
Tonino, Sanne
Kap, Marcel
Liu, Roberto D.
Chamuleau, Martine E. D.
Visser, Hein P. J.
De Jongh, Eva
Marijt, Erik Waf
Leijs, Maria B. L.
Bilgin, Yavuz M.
Duerig, Jan
McKay, Pamela
Snijders, Tjeerd J. F.
Pettitt, Andrew
Minnema, Monique C.
Prange-Krex, Gabriele
Cuijpers, Maria
Boehmer, Lara H.
Tick, Lidwine W.
Florschuetz, Axel
Silbermann, Matthijs
Fijnheer, Rob
Beeker, Aart
Tolboom, Nelleke
Mitea, Cristina
Arens, Anne I. J.
Zwezerijnen, Gerben J. C.
Klapper, Wolfram
Coupland, Sarah E.
de Jong, Daphne
Doorduijn, Jeanette K.
Zijlstra, Josee M.
BLOOD, 2022, 140 : 2283 - 2285
[27] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (PANORAMA 1)
San-Miguel, J.
Hungria, V. T.
Yoon, S. S.
Beksac, M.
Dimopoulos, M. A.
Elghandour, A.
Jedrzejczak, W. W.
Guenther, A.
Nakorn, T. Na
Siritanaratkul, N.
Schlossman, R. L.
Hou, J.
Moreau, P.
Lonial, S.
Lee, J. H.
Einsele, H.
Salwender, H.
Sopala, M.
Bengoudifa, B. R.
Corrado, C.
Binlich, F.
Richardson, P.
HAEMATOLOGICA, 2014, 99 : 219 - 220
[28] Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
Fogelman, David
Cubillo, Antonio
Garcia-Alfonso, Pilar
Limon Miron, Maria Luisa
Nemunaitis, John
Flora, Daniel
Borg, Christophe
Mineur, Laurent
Vieitez, Jose M.
Cohn, Allen
Saylors, Gene
Assad, Albert
Switzky, Julie
Zhou, Li
Bendell, Johanna
CANCER MEDICINE, 2018, 7 (11): : 5382 - 5393
[29] Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
Richardson, Paul G.
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw W.
Guenther, Andreas
Nakorn, Thanyaphong Na
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae Hoon
Einsele, Hermann
Sopala, Monika
Bengoudifa, Bourras-Rezki
Corrado, Claudia
San-Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[30] Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).
Noy, Ariela
Hughes, Stephanie
Biggar, Erin
Bogdan, Matthew
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →